
  
    
      
        
        Despite_IN the_DT significant_JJ progress_NN in_IN increasing_VBG our_PRP$ understanding_NN of_IN the_DT immune_JJ
        mechanisms_NNS of_IN multiple_JJ sclerosis_NN (_( MS_NNP )_) ,_, in_IN improving_VBG clinical_JJ classification_NN and_CC brain_NN
        imaging_NN ,_, and_CC in_IN developing_VBG new_JJ treatments_NNS ,_, the_DT factors_NNS that_WDT determine_VBP the_DT course_NN of_IN the_DT
        disease_NN are_VBP mostly_RB unknown_JJ [_NN 1_CD ]_NN ._. Currently_RB ,_, it_PRP is_VBZ nearly_RB impossible_JJ to_TO predict_VB the_DT course_NN of_IN
        MS_NNP ,_, its_PRP$ severity_NN in_IN terms_NNS of_IN disability_NN progression_NN ,_, or_CC when_WRB a_DT relapse_NN will_MD happen_VB ._.
        The_DT most_RBS commonly_RB used_VBN disease-modifying_JJ therapies_NNS are_VBP interferon_NN β_NN (_( IFNβ_NNP )_) [_NN 2_CD ]_NN and_CC
        glatiramer_NN acetate_NN [_NN 2_CD ,_, 3_CD ]_NN ._. Despite_IN initial_JJ excitement_NN ,_, these_DT therapies_NNS have_VBP beneficial_JJ
        effects_NNS in_IN some_DT ,_, but_CC not_RB all_DT ,_, patients_NNS [_NN 2_CD ,_, 3_CD ]_NN ._. Because_IN of_IN the_DT potential_JJ favorable_JJ effects_NNS of_IN
        these_DT therapies_NNS ,_, it_PRP has_VBZ been_VBN suggested_VBN that_IN they_PRP should_MD be_VB initiated_VBN as_RB early_RB as_IN possible_JJ
        to_TO maximize_VB neuroprotection_NN [_NN 4_CD ]_NN ._. Additionally_RB ,_, it_PRP has_VBZ been_VBN recommended_VBN that_IN patients_NNS should_MD
        be_VB monitored_VBN closely_RB to_TO determine_VB whether_IN and_CC when_WRB it_PRP is_VBZ necessary_JJ to_TO modify_VB treatment_NN in_IN
        order_NN to_TO maximize_VB the_DT benefit_NN [_NN 5_CD ]_NN ._. The_DT recommended_VBD monitoring_VBG is_VBZ based_VBN on_IN annual_JJ rate_NN of_IN
        relapses_NNS ,_, neurological_JJ deterioration_NN ,_, and_CC evidence_NN of_IN disease_NN activity_NN on_IN brain_NN magnetic_JJ
        resonance_NN imaging_NN scans_NNS ._. However_RB ,_, given_VBN the_DT destructive_JJ nature_NN of_IN the_DT disease_NN ,_, if_IN we_PRP rely_VBP
        solely_RB on_IN clinical_JJ or_CC radiological_JJ manifestations_NNS (_( such_JJ as_IN a_DT relapse_NN or_CC a_DT new_JJ lesion_NN on_IN a_DT
        scan_VB )_) to_TO determine_VB a_DT patient_NN 's_POS response_NN to_TO therapy_NN ,_, we_PRP will_MD probably_RB be_VB responding_VBG too_RB
        late_RB ._.
      
      
        Gene_NNP Expression_NNP Patterns_NNS in_IN Affected_NNP Organs_NNP
        The_DT diagnosis_NN and_CC management_NN of_IN disease_NN could_MD be_VB transformed_VBN thanks_NNS to_TO the_DT completion_NN of_IN
        the_DT human_JJ genome_NN project_NN ,_, the_DT availability_NN of_IN sequence_NN information_NN for_IN nearly_RB every_DT gene_NN ,_,
        and_CC the_DT advent_NN of_IN novel_NN high_JJ throughput_NN technologies_NNS (_( microarrays—see_NN Glossary_NNP )_) that_WDT allow_VBP
        parallel_JJ profiling_VBG of_IN thousands_NNS of_IN genes_NNS ._. By_IN definition_NN ,_, nearly_RB every_DT aspect_NN of_IN a_DT disease_NN
        phenotype_NN should_MD be_VB represented_VBN in_IN gene_NN expression_NN signatures_NNS of_IN multiple_JJ genes_NNS in_IN the_DT
        affected_VBN organ_NN ._. Indeed_RB ,_, studies_NNS that_WDT analyze_VBP affected_VBN tissues_NNS (_( mostly_RB in_IN cancer_NN )_) clearly_RB
        show_NN that_IN it_PRP is_VBZ possible_JJ to_TO predict_VB prognosis_NN ,_, to_TO identify_VB new_JJ classes_NNS of_IN diseases_NNS ,_, and_CC
        potentially_RB to_TO determine_VB response_NN to_TO therapy_NN [_NN 6_CD ,_, 7_CD ,_, 8_CD ]_NN ._.
        In_IN diseases_NNS that_WDT do_VBP not_RB require_VB tissue_NN resection_NN for_IN diagnosis_NN or_CC therapy_NN ,_, it_PRP is_VBZ rare_JJ to_TO
        obtain_VB tissues_NNS for_IN analysis_NN ._. This_DT problem_NN is_VBZ even_RB more_RBR pronounced_JJ in_IN diseases_NNS like_IN MS_NNP ,_, in_IN
        which_WDT the_DT target_NN organ_NN is_VBZ the_DT very_RB inaccessible_JJ brain_NN and_CC spinal_JJ cord_NN ._. Despite_IN these_DT
        limitations_NNS ,_, several_JJ groups_NNS used_VBD microarrays_NNS to_TO analyze_VB brain_NN tissues_NNS obtained_VBN posthumously_RB
        from_IN patients_NNS who_WP had_VBD MS_NNP and_CC identified_VBN genes_NNS that_WDT characterized_VBD either_DT acute_JJ or_CC chronic_JJ
        lesions_NNS [_NN 9_CD ,_, 10_CD ,_, 11_CD ]_NN ._. However_RB ,_, although_IN these_DT studies_NNS identified_VBD some_DT potential_JJ genes_NNS that_WDT may_MD
        be_VB involved_VBN in_IN the_DT local_JJ pathogenesis_NNS of_IN the_DT disease_NN ,_, they_PRP did_VBD not_RB produce_VB any_DT information_NN
        that_WDT could_MD be_VB used_VBN for_IN identifying_VBG biomarkers_NNS associated_VBN with_IN disease_NN activity_NN ._.
      
      
        Diagnostic_NNP Peripheral_NNP Blood_NNP Mononuclear_NNP Cell_NNP Gene_NNP Expression_NNP Signatures_NNP
        In_IN MS_NNP ,_, looking_VBG for_IN markers_NNS of_IN disease_NN activity_NN in_IN the_DT much_RB more_RBR accessible_JJ peripheral_JJ
        blood_NN does_VBZ not_RB require_VB a_DT significant_JJ leap_NN of_IN faith_NN ._. MS_NNP is_VBZ an_DT autoimmune_JJ disease_NN ,_, and_CC it_PRP is_VBZ
        possible_JJ that_IN some_DT of_IN the_DT cells_NNS involved_VBN in_IN the_DT pathogenesis_NNS of_IN the_DT disease_NN will_MD be_VB found_VBN
        in_IN the_DT bloodstream_NN ._. Abnormal_NNP T_NN cell_NN populations_NNS have_VBP repeatedly_RB been_VBN observed_VBN in_IN the_DT
        peripheral_JJ blood_NN of_IN patients_NNS with_IN MS_NNP [_NN 12_CD ,_, 13_CD ,_, 14_CD ]_NN ._. While_IN these_DT results_NNS supported_VBD looking_VBG at_IN
        the_DT easily_RB accessible_JJ peripheral_JJ blood_NN mononuclear_NN cells_NNS (_( PBMCs_NNP )_) for_IN potential_JJ markers_NNS that_WDT
        reflect_VBP the_DT disease_NN ,_, some_DT doubts_NNS persisted_VBD ._. These_DT revolved_JJ around_IN two_CD very_RB strong_JJ
        arguments_NNS ._. The_DT first_JJ argument_NN was_VBD that_IN if_IN the_DT signal_NN comes_VBZ from_IN a_DT minority_NN of_IN the_DT cells_NNS
        within_IN the_DT bloodstream_NN it_PRP will_MD be_VB too_RB low_JJ to_TO be_VB detected_VBN ._. The_DT second_RB was_VBD that_DT interpersonal_NN
        variability_NN ,_, added_VBD to_TO the_DT inherent_JJ noisy_NN nature_NN of_IN gene_NN expression_NN data_NNS ,_, will_MD make_VB the_DT data_NNS
        impossible_JJ to_TO reproduce_VB ._.
        Fortunately_RB ,_, recent_JJ observations_NNS suggest_VBP that_IN these_DT doubts_NNS are_VBP unfounded_JJ ._. Bomprezzi_NNP et_CC
        al_NN ._. [_NN 15_CD ]_NN determined_VBN that_DT gene_NN expression_NN patterns_NNS can_MD distinguish_VB patients_NNS with_IN MS_NNP from_IN
        controls_NNS and_CC suggested_VBD that_IN at_IN least_JJS some_DT of_IN the_DT differences_NNS identified_VBN were_VBD derived_VBN from_IN
        activated_VBN T_NN cells_NNS ._. Achiron_NNP et_CC al_NN ._. [_NN 16_CD ]_NN analyzed_VBD the_DT expression_NN of_IN 12_CD ,_, 000_CD genes_NNS in_IN patients_NNS
        with_IN relapsing–remitting_VBG MS_NNP ._. Gene_NNP expression_NN patterns_NNS clearly_RB distinguished_VBD patients_NNS with_IN
        MS_NNP from_IN controls_NNS as_RB well_RB as_IN relapse_NN from_IN remission_NN ._. Mandel_NNP et_CC al_NN ._. [_NN 17_CD ]_NN compared_VBD patients_NNS
        with_IN systemic_JJ lupus_JJ erythematosus_JJ and_CC MS_NNP ,_, and_CC identified_VBD a_DT common_JJ autoimmunity_NN signature_NN as_RB
        well_RB as_IN disease-specific_JJ gene_NN expression_NN signatures_NNS ._. Interestingly_RB ,_, similar_JJ findings_NNS were_VBD
        recently_RB described_VBN for_IN pulmonary_JJ arterial_NN hypertension_NN [_NN 18_CD ]_NN ._.
      
      
        Could_MD PBMC_NNP Gene_NNP Expression_NNP Signatures_NNP Be_VB Used_VBN for_IN Predicting_VBG Response_NNP to_TO
        Therapy_NNP ?_.
        Weinstock-_NNP Guttman_NNP et_CC al_NN ._. [_NN 19_CD ]_NN analyzed_VBD the_DT acute_JJ transcriptional_NN response_NN of_IN 4_CD ,_, 000_CD genes_NNS
        in_IN peripheral_JJ blood_NN lymphocytes_NNS to_TO IFNβ_NNP ._. They_PRP identified_VBD increases_NNS in_IN known_VBN
        interferon-inducible_JJ genes_NNS ,_, and_CC in_IN genes_NNS involved_VBN in_IN antiviral_JJ activity_NN and_CC interferon_NN
        signaling_VBG ._. Using_VBG complementary_JJ DNA_NNP (_( cDNA_NN )_) arrays_NNS ,_, Sturzebecher_NNP et_CC al_NN ._. [_NN 20_CD ]_NN identified_VBD gene_NN
        expression_NN signatures_NNS that_WDT distinguished_VBD IFNβ_NNP responders_NNS from_IN nonresponders_NNS ._.
        And_CC now_RB ,_, in_IN a_DT new_JJ study_NN published_VBN in_IN last_JJ month_NN 's_POS 
        PLoS_NNP Biology_NNP ,_, Baranzini_NNP et_CC al_NN ._. [_NN 21_CD ]_NN provide_VB compelling_JJ evidence_NN that_IN
        these_DT PBMC_NNP gene_NN expression_NN signatures_NNS can_MD be_VB used_VBN to_TO predict_VB response_NN to_TO therapy_NN (_( Figure_NN
        1_LS )_) ._. They_PRP studied_VBD the_DT expression_NN of_IN 70_CD genes_NNS selected_VBN for_IN their_PRP$ presumed_VBN biological_JJ function_NN
        in_IN 52_CD patients_NNS with_IN MS_NNP ,_, followed_VBD up_RP for_IN at_IN least_JJS two_CD years_NNS after_IN initiation_NN of_IN IFNβ_NNP
        therapy_NN ._. Instead_RB of_IN using_VBG microarrays_NNS that_WDT carry_VBP probes_NNS for_IN thousands_NNS of_IN genes_NNS ,_, they_PRP chose_VBD
        to_TO use_VB real-time_JJ PCR_NNP ._. This_DT method_NN is_VBZ highly_RB sensitive_JJ ,_, specific_JJ ,_, and_CC reproducible_JJ across_IN
        different_JJ laboratories_NNS ._. It_PRP is_VBZ often_RB used_VBN to_TO verify_VB microarray_NN findings_NNS ._. Baranzini_NNP et_CC al_NN ._.
        identified_VBN MX_NNP 1_CD (_( interferon-inducible_JJ protein_NN p_NN 78_CD )_) ,_, a_DT known_VBN interferon-inducible_JJ gene_NN ,_, as_IN
        the_DT marker_NN of_IN treatment_NN with_IN IFNβ_NNP ._. They_PRP did_VBD not_RB find_VB overall_JJ differences_NNS between_IN responders_NNS
        and_CC nonresponders_NNS ,_, but_CC they_PRP did_VBD ,_, using_VBG supervised_JJ classification_NN methods_NNS ,_, identify_VB triplets_NNS
        of_IN genes_NNS that_WDT distinguish_VB IFNβ_NNP responders_NNS and_CC nonresponders_NNS ._.
        Interestingly_RB ,_, individual_JJ and_CC pairs_NNS of_IN genes_NNS did_VBD not_RB perform_VB that_IN well_RB ,_, and_CC all_DT three_CD
        genes_NNS in_IN a_DT triplet_NN were_VBD required_VBN for_IN the_DT highest_JJS accuracy_NN (_( about_IN 80_CD %_NN –_NN 90_CD %_NN )_) ._. The_DT minimal_JJ
        combinatorial_NN number_NN of_IN genes_NNS that_WDT contains_VBZ the_DT most_RBS predictive_JJ information_NN is_VBZ not_RB
        available_JJ since_IN combinations_NNS of_IN more_JJR than_IN three_CD genes_NNS were_VBD not_RB performed_VBN ._. Although_IN the_DT
        results_NNS were_VBD not_RB tested_VBN on_IN an_DT independent_JJ dataset_NN ,_, as_IN is_VBZ frequently_RB requested_VBN [_NN 22_CD ]_NN ,_, the_DT
        authors_NNS applied_VBD an_DT array_NN of_IN cross-validation_JJ strategies_NNS that_WDT convincingly_RB suggested_VBD that_IN
        the_DT identified_VBN predictive_JJ signal_NN was_VBD robust_JJ ._.
      
      
        Implications_NNP of_IN the_DT Study_NNP
        What_WP could_MD Baranzini_NNP and_CC colleagues_NNS '_POS findings_NNS mean_VBP ?_. Clearly_RB ,_, the_DT most_RBS obvious_JJ conclusion_NN
        is_VBZ that_IN the_DT lack_NN of_IN response_NN did_VBD not_RB result_VB from_IN the_DT deactivation_NN of_IN IFNβ_NNP ._. The_DT effect_NN of_IN
        IFNβ_NNP on_IN MX_NNP 1_CD ,_, IFNAr_NNP 1_CD ,_, and_CC STAT_NNP 2_CD was_VBD observed_VBN for_IN two_CD years_NNS in_IN all_DT patients_NNS ,_, suggesting_VBG that_IN
        the_DT response_NN did_VBD not_RB depend_VB on_IN IFNβ_NNP bioavailability_NN ._. Considering_VBG that_IN PBMCs_NNP represent_VB an_DT
        admixture_NN of_IN multiple_JJ cell_NN types_NNS ,_, the_DT most_RBS plausible_JJ explanation_NN is_VBZ a_DT simple_JJ lack_NN of_IN shift_NN
        in_IN subcellular_NN populations_NNS ._.
        However_RB ,_, the_DT importance_NN of_IN Baranzini_NNP and_CC colleagues_NNS '_POS study_NN lies_VBZ not_RB in_IN its_PRP$ mechanistic_JJ
        insights_NNS ,_, but_CC in_IN its_PRP$ clinical_JJ relevance_NN ._. The_DT careful_JJ design_NN of_IN the_DT experiment_NN ,_, the_DT use_NN of_IN
        reproducible_JJ real-time_JJ PCR_NNP instead_RB of_IN microarrays_NNS ,_, the_DT meticulous_JJ analysis_NN ,_, and_CC the_DT
        previous_JJ observations_NNS [_NN 15_CD ,_, 16_CD ,_, 17_CD ,_, 19_CD ,_, 20_CD ]_NN support_NN the_DT notion_NN that_IN PBMCs_NNP express_VB clinically_RB
        relevant_JJ gene_NN expression_NN signatures_NNS in_IN MS_NNP and_CC probably_RB in_IN other_JJ organ-confined_JJ diseases_NNS ._. To_TO
        further_VB prove_VB this_DT notion_NN will_MD require_VB a_DT significant_JJ investment_NN in_IN large_JJ studies_NNS that_WDT
        prospectively_RB test_NN the_DT utility_NN of_IN these_DT signatures_NNS in_IN guiding_VBG the_DT management_NN of_IN MS_NNP ._. Only_RB
        when_WRB direct_JJ evidence_NN shows_VBZ that_DT therapy_NN guided_VBN by_IN markers_NNS expressed_VBD in_IN PBMCs_NNP improves_VBZ
        patient_NN outcome_NN will_MD PBMC_NNP gene_NN expression_NN patterns_NNS take_VBP their_PRP$ place_NN as_IN biomarkers_NNS at_IN the_DT
        center_NN stage_NN of_IN monitoring_VBG MS_NNP progression_NN and_CC response_NN to_TO therapy_NN ._.
      
    
  
